Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank-check company formed to pursue an acquisition in the biomedical and life sciences sector. Sponsored by Eucrates Biomedical LLC, the company completed its initial public offering in 2021 and was actively searching for a target business at the time of its August 2022 Form 10-Q filing with the SEC, accession number 0001410578-22-002601. The vehicle was structured to focus on opportunities within healthcare and biomedical innovation, reflecting continued SPAC sponsor interest in the life sciences space during that period. Visit SpacDesk and sign up for full data, filings history, and deal-tracking on EUCR and hundreds of other SPACs.